Novo Nordisk reduced prices of its weight-loss drugs Wegovy and Ozempic by up to 48% in India due to competition from low-cost generics. Despite recent FDA approvals for new treatments and a strong drug pipeline, the company's shares have dropped 43% over the past year amid concerns over pricing power and market share losses to Eli Lilly. Investor sentiment has shifted from bullish to cautious, with analysts divided on the stock's outlook. The upcoming FDA decision on the new drug CagriSema later in 2026 is seen as a key catalyst for the company's future performance.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
